SHame PrOpensity in BOrderline Personality Disorder

Last updated: January 14, 2025
Sponsor: University Hospital, Montpellier
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mood Disorders

Schizotypal Personality Disorder (Spd)

Borderline Personality Disorder

Treatment

Clinical and biological assessments - a 5 Years follow-up

Clinical Study ID

NCT03994510
UF 7681
  • Ages > 18
  • All Genders

Study Summary

Borderline Personality Disorder (BPD) is a common psychiatric disorder occurring in 2 to 6% of the population. 70% of patients with BPD do at least one Suicide Attempt (SA) in their lives. It makes BPD the most related to SA condition.

Negative interpersonal events are among the main stressor inducing a SA. Patients with BPD are characterized by emotional dysregulation, impulsivity (repeated parasuicidal and suicidal behaviors), and instability in interpersonal relationships. The feeling of shame related to this psychiatric disorder could be one of the causes of the high SA rate. In this study, patients with BPD will be follow-up during 5 years.

The main objective is to study the propensity to feel shame as a predictor of SA.

This include:

  • Study of shame propensity as a predictive factor of suicidal behavior - Identify homogeneous subgroups of patients with BPD based on SA, and overall functioning.

  • Identify biological markers predicting SA

  • Identify predictive and protective treatments (pharmacological and psychotherapeutic) for SA

Eligibility Criteria

Inclusion

Inclusion criteria:

  • To be over 18

  • Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview forDSM-IV-Text Reviewed Axis II Personality Disorders)

  • Having signed the informed consent

  • Able to understand the nature, the purpose and the methodology of the study

  • Able to understand and perform the clinical evaluations

Exclusion

Exclusion criteria:

  • Deprived of liberty (by judicial or administrative decision)

  • Protected by law (guardianship)

  • Exclusion period in relation to another protocol

  • Not affiliated to a social security scheme

Study Design

Total Participants: 688
Treatment Group(s): 1
Primary Treatment: Clinical and biological assessments - a 5 Years follow-up
Phase:
Study Start date:
September 18, 2020
Estimated Completion Date:
September 30, 2031

Study Description

This is a 5 years follow-up prospective study recruiting 688 patients.

Schedule of the study :

Inclusion period : 3 years Duration of follow-up of each patient : 5 years Estimated duration of the study : 8.5 years

As part of the research, patients will be summoned annually for 5 years.

The first visit (at baseline) is included in the usual care

The follow-up visits are specifics to the research

During the visits patients will complete self questionary and clinical interview.

The organization of visits is as follows:

  • an inclusion visit lasting around 2 hours (clinical evaluation and then self-questionnaires)

  • a visit to 1 year, 2 years, 3 years, 4 years and 5 years (+/- 1 month) lasting approximately 1 hour 30 (clinical evaluation and passing of self-questionnaires)

Genetic samples will be taken during the initial visit as well as during the visit to 5 years.

They consist of:

  • A genetic collection consisting of a DNA library (3 Ethylene Diamine Triacetic Acid (EDTA) tubes of 6ml - 18 ml).

  • An off-genetics collection consisting of serum and plasma samples, (1 6 ml EDTA tube, 1 4 ml heparinized tube, 2 dry tubes of 5 ml each and 2 citrated tubes of 2.7 ml each - 25 , 4 ml).

Connect with a study center

  • University Hospital of Montpellier

    Montpellier, Hérault 34295
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.